P-57: Ultrastructural Study of GnRH Potential in Inhibition of Side Effect of Drugs Used in Chemoterapy on Basal Lamina of Seminiferous Tubules of Mice

Background: Male factors, mainly spermatogenesis disorder, are responsible for 20-30% of infertility occurs in different societies. One of the known causes of spermatogenesis disorder is chemotherapy in patients with cancer. The side effect of chemoterpic agents may last from 10 years up to the end of the life. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH antagonist as a suppressor of spermatognial proliferation, on spermatogenic defect produced by anticancer drug (thiotepa). Materials and Methods: In the present study 30 adult male mice aging 6-8 weeks were used. The mice were divided into 3 equal groups as; control, thiotcpa (T group) and thiotepa + cetrorelix, a GnRH antagonist, (T + C group). Thiotcpa was injectctcd as ip for 5 days at 2.5 mg/kg doses. In T+C group cetrorelix injection was started one week before thiotepa treatment and continued for 3 more weeks. Results: Electron microscopic study showed that in control group BL was regular and had two layers, dense and clear that spermatogonium and sertoli cells lie on it. In T group BL was irregular and wavy and amount of collagen fibers appeared high. On the other hand, there were large spaces between BL and spermatogonium and sertoli cells. In T+C group BL was similar to control group. Conclusion: According to the result it is concluded that GnRH antagonist administration before cancer treatment could prevent the side effect of anticancer drugs.